DAPT-CHF Subgroup Analysis Index Calculator

Clinical calculation support · Verify results before clinical use

Index calculation

Enter patient characteristics to calculate the arithmetic index implemented in the original template.

0Index

Enter age from 18 to 120 years.

Enter a percentage from 5 to 80.

Heart failure present

Select whether the patient has heart failure.

Diabetes mellitus

Select whether diabetes mellitus is present.

Prior myocardial infarction (MI)

Select whether there is a history of MI.

Stent diameter < 3 mm

Select yes if the relevant stent diameter is below 3 mm.

History of bleeding

Select whether there is a history of bleeding.

0Index
Original-template category (unvalidated)
Neutral range
The score is an arithmetic output, not a validated estimate of clinical risk.
Clinical context

This custom index has not been established as a validated decision rule. Do not use it alone to determine DAPT duration.

Important safety notice: This is an exploratory, unvalidated index based on the original supplied code. It does not calculate a validated probability of ischemia or bleeding and must not be used to start, stop, or extend antiplatelet therapy. Review ischemic and bleeding risks with validated instruments and the applicable guideline, alongside patient-specific clinical judgment.

About this index

The supplied template combines age, diabetes, prior MI, stent diameter, bleeding history, heart failure status, and LVEF into a single arithmetic score. The combination and the resulting categories should be treated as a locally constructed heuristic rather than a validated clinical prediction model.

Weights implemented from the original file

VariableRule in original codePoints
Age ≥75 yearsAge 75 years or older−2
Age 65 to <75 yearsAge at least 65 and below 75−1
Diabetes mellitusPresent+1
Prior MIPresent+1
Stent diameter <3 mmPresent+1
History of bleedingPresent−1
Heart failurePresent−1
LVEF <40%Present−1

Interpretation limits

The original template assigned categories at scores ≥2, 0–1, and below 0. These are displayed only as legacy categories for transparency; no clinical benefit, bleeding probability, or treatment recommendation can be inferred from those cutoffs without external validation.

In particular, the validated DAPT Score uses a different set of variables and weights. A history of bleeding is not a component of the original DAPT Score, and the original score assigns +2 for congestive heart failure or LVEF <30%, rather than the separate negative weights used here. The custom index must not be presented as the validated DAPT Score.

References and evidence

Yeh RW, Secemsky EA, Kereiakes DJ, et al.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749.

doi:10.1001/jama.2016.3775

Mauri L, Kereiakes DJ, Yeh RW, et al.

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2014;371:2155–2166.

doi:10.1056/NEJMoa1409312

Yeh RW, Kereiakes DJ, Steg PG, et al.; DAPT Study Investigators.

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015;65(20):2211–2221.

doi:10.1016/j.jacc.2015.03.003

The supplied file cites a heart-failure subgroup paper under a title that could not be verified as written during this review. It has therefore not been retained as a verified reference for a CHF-specific index.

Clinical disclaimer: This tool is intended for educational exploration of the formula in the supplied template. The index has not been shown here to have external validation, calibration, discrimination, or demonstrated clinical utility. It is not a substitute for the validated DAPT Score, a formal bleeding-risk assessment, current guidelines, or individualized clinician-patient decision-making.